Vaxcell-Bio Therapeutics

박셀바이오 · 323990

Health Care Biotechnology · KOSDAQ

Small-cap

Market cap US$90.2M (₩124.4B)

Overview

Vaxcell-Bio Therapeutics develops cell-based therapies, treatments that use a patient's own immune cells to fight disease, with a focus on cancer immunotherapy.

Its products are aimed at clinical and hospital settings where patients require advanced biological treatments. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange, and is currently in a development-stage phase, generating revenue while continuing to invest heavily in research.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$5.1M

▲ +271.6% YoY

Operating profit · FY2025

−US$11.2M

Loss widened

Net income · FY2025

−US$9.7M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$9.9K(₩13.7M)	US$1.4M(₩1.9B)	US$5.1M(₩7.1B)
Operating profit	−US$8.3M(−₩11.5B)	−US$10.9M(−₩15B)	−US$11.2M(−₩15.5B)
Net income	−US$7.4M(−₩10.3B)	−US$7.7M(−₩10.6B)	−US$9.7M(−₩13.3B)

Revenue

FY2023US$9.9K
FY2024US$1.4M
FY2025US$5.1M

Operating profit

FY2023−US$8.3M
FY2024−US$10.9M
FY2025−US$11.2M

Net income

FY2023−US$7.4M
FY2024−US$7.7M
FY2025−US$9.7M

Key ratios (FY2025)

ROE

-21.8%

Debt/Eq

9.4%

Op. margin

-219.6%

Net margin

-189.1%

Rev. YoY

▲ +271.6%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?